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The purpose of this study was to investigate the comparative efficacy and safety of equal doses of inhaled 
fluticasone propionate (FP) and inhaled budesonide (BUD) using their respective dry powder inhalers in a 
population of severe asthmatics requiring high doses of inhaled corticosteroid. This double-blind double-dummy 
parallel-group study compared the effects of 24 weeks of treatment with FP (2000 pg daily via a Diskhaler@ 
inhaler; Glaxo Wellcome, Evreux, France) and BUD (2000 pg daily via a Turbuhale? inhaler; Astra 
Pharmaceuticals, Rijswijka, Netherlands) on lung function and asthma exacerbations in 395 patients with asthma. 
FP was statistically significantly superior to BUD with respect to the percentage of symptom-free days 
(P = 0.02), the incidence of days free from rescue bronchodilator usage (P = O-02) and the distribution of change 
in peak expiratory flow (PEF) expressed as a percentage of the predicted PEF (P = 0.04). During the treatment 
period FP was statistically significantly superior to BUD for change in forced expiratory volume in I set (FEV1) at 
8, 16 and 24 weeks, change in the median daytime symptom score during weeks 5-16, for incidence of symptom- 
Ifree days and incidence of days free from rescue bronchodilator usage during weeks 11-24. There was no significant 
difference between FP and BUD with respect to the number of patients experiencing one or more asthma 
exacerbation (33.8 and 28.4% of patients, respectively). There was, however, evidence that the exacerbations were 
clinically less severe in patients treated with FP, in that the time to resolution was quicker (11.0 vs. 14.7 days; 
P = 0.035), mean duration of all exacerbations (for an individual patient) tended to be shorter (18.5 vs. 23.6 days; 
P = 0.12), the time off work was reduced (4.2 vs. 7.6 days; P = 0.012) and the lowest PEF recorded during the 
exacerbation was higher (301 vs. 263 1 min-‘; P = 0.07). There were no clinically relevant differences in the safety 
(serum cortisol levels, markers of bone turnover, adverse events) of FP and BUD at these microgram equivalent 
doses. 
The patients recruited into this study, in retrospect, probably had no need for such high doses of inhaled 
corticosteroid but, irrespective of this, FP at microgram equivalent doses showed evidence of superior efficacy to 
BUD with respect to lung function and severity of asthma exacerbations without producing any greater adverse 
systemic effect. 
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Introduction 
The comparative therapeutic profiles of fluticasone propio- 
nate (FP) and budesonide (BUD) in asthma patients, 
administered by either metered-dose inhalers (MDIs) or dry 
powder inhalers (DPIs), have been established in numerous 
clinical trials in which efficacy (measured by peak 
expiratory flow; PEF) and safety (measured by morning 
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serum cortisol level) have been compared within studies. In 
two separate studies involving patients with mild/moderate 
asthma (1,2) increasing the daily dose of FP from 100 pg up 
to 800 ,ug produced a significant dose-related increase in 
both morning and evening PEF. In an attempt to obtain an 
overview of the comparative efficacy and safety of FP, 
BUD and BDP, a meta-analysis (3) of all trials directly 
comparing FP and BUD (1,4,5-9), and FP and BDP (2,10- 
15), in which morning peak flow was an outcome measure 
and drugs were compared at the 2: 1 dose ratio, has been 
performed. The meta-analysis found the pooled value of the 
mean morning PEF to be significantly higher with FP than 
with a dose of BUD of at least twice the,FP dose (3). Also, 
across five studies, the pooled value qf plasma cortisol level 
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following FP was significantly greater than that following 
BUD (3). In the studies comparing FP at half the dose to 
BDP, the pooled analysis of improvement in mean morning 
PEF showed a non-significant trend in favour of FP and 
there was no significant difference between FP and BDP in 
plasma cortisol levels (3). 
In a study of patients with severe asthma, the mean 
serum cortisol increased in patients treated with FP 1000 pg 
daily, while it was reduced in patients treated with BDP 
2000 vg daily, suggesting an increased therapeutic benefit 
in favour of FP (10). In similar studies involving patients 
with severe asthma, no statistically significant suppression 
of serum cortisol levels was observed following adminis- 
tration with FP and BDP both at 1500 ,ug daily (16) and the 
suppression of serum cortisol levels observed with FP 
1000 pg was less than the suppression seen with BUD 
1600 /Lg (17). 
Both FP and BUD are commercially available as dry 
powder formulations; it has been established that FP is 
equally safe and effective when administered by either MD1 
or DPI (l&20), but the deposition of BUD is greater when 
administered as a dry powder than via its MD1 (21). The 
purpose of this study was to investigate the comparative 
efficacy and safety of equal doses of FP and BUD in a 
population of severe asthmatics requiring high doses of 
inhaled corticosteroid. The study used the highest recom- 
mended dose of FP which has been shown in previous 
studies to have a favourable risk: benefit ratio (17,22-26). 
The study gave particular emphasis to the incidence and 
severity of asthma exacerbations, which can be considered 
to be a clinically relevant end-point in this population of 
patients. This study is the first in which a specifically 
designed module was used to collect information on asthma 
exacerbations. 
Methods 
STUDY DESIGN 
This double-blind, double-dummy, parallel-group study 
was conducted in 47 centres in four different countries 
(Belgium, Canada, Denmark, The Netherlands): and 
consisted of a 2-week run-in period, a 24-week treatment 
period with either FP or BUD 2000 yg daily, and a 2-week 
follow-up period. The study was conducted in accordance 
with the Declaration of Helsinki and its amendments, and 
conformed to good clinical practice. The local medical 
ethics committee at each centre approved the protocol for 
the study. 
PATIENTS 
Symptomatic patients, aged IS-75 years, with a documen- 
ted history of (in the previous 12 months), or pre-study 
evidence of, reversible airways disease [change in forced 
expiratory volume in 1 set (FEVi) > 15% in the 15 min 
following administration of salbutamol 400 or 800 pg]> 
requiring or responding to treatment with inhaled BDP or 
BUD 1500-2000 pg daily or FP 750-1000 pg daily, were 
considered for enrolment into the study. Patients with 
serious uncontrolled systemic disease (including bone 
disease) at the start of the run-in period, and patients 
who had required treatment with oral steroids or were 
being treated with research medication within 1 month of 
the start of the run-in period, were not considered eligible 
for the study. Pregnant and lactating women were also not 
eligible. The aim of the study and a detailed explanation of 
the patient’s involvement in the study (including the 
decision by the patient to withdraw for any reason) were 
provided by the investigator before patients gave written 
informed consent to participate in the study. 
RUN-IN PERIOD 
Patients continued their existing medication throughout the 
run-in period with the exception that the only permissible 
inhaled bronchodilator was salbutamol, which was to be 
used on an ‘as required’ basis to relieve symptoms of 
reversible airways obstruction. Each day the patient 
completed a diary card with respect to morning and 
evening peak expiratory flow (PEF; highest of three 
consecutive readings), severity of daytime (score of O-5) 
and night-time (score of O-4) asthma symptoms and 
number of doses of inhaled salbutamol used. At the end 
of the run-in period the reversibility challenge to salbuta- 
mol was repeated and patients were allocated to study 
treatment if: there was demonstrable reversible airways 
disease; their mean morning PEF during the last 7 days of 
the run-in period was <85% of the post-salbutamol 
challenge PEF; the mean daytime symptom score was 22 
on at least 7 days during the run-in period; and the 
investigator was satisfied that the patient was able to use 
the Diskhaler@ and Turbuhalera correctly. 
TREATMENT PERIOD 
Patients were randomly allocated to treatment with either 
FP 1000 pg twice daily or BUD 1200 pg in the mornings 
and 800 pg in the evenings. Patients were also provided 
with placebo inhalers of the alternative device in order to 
maintain blinding. During the 24-week treatment period 
patients were permitted to take methylxanthines, anti- 
cholinergics, nedocromil, sodium cromoglycate, ketotifen 
and long-acting P-agonists on the understanding that the 
dose remained unchanged during the study. Intranasal 
corticosteroids were permissible within the recommended 
dose-range for the particular preparation, as was the 
administration of anti-fungal lozenges for the treatment 
of oropharyngeal candidiasis. Full details of concomitant 
medication (including changes in dose) were recorded at 
each study visit. Patients completed the diary card each 
day, and attended the clinic every 4 weeks during the first 8 
weeks of treatment and then every 8 weeks. At these clinic 
visits patients’ FEVl, forced vital capacity (FVC) and PEF 
were measured and recorded. 
There was a 2-week follow-up period either at the end of 
the treatment period or after withdrawal of the patient from 
the study. At a clinic visit at the end of this period FEVr, 
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FVC and PEF were recorded, but no diary card was 
completed between the end of the treatment period and this 
follow-up visit. 
EXACERBATIONS 
Patients who experienced worsening asthma symptoms 
were asked to increase their use of rescue salbutamol in an 
attempt to obtain symptomatic relief, contact the investi- 
gator, general practitioner or primary care physician, report 
to the clinic within 24 h of the onset of exacerbations and 
record their symptom score, PEF and bronchodilator usage 
on their diary cards. The investigator decided whether or 
not to initiate treatment with oral steroids. The dose of oral 
steroid was only reduced when there was clinical evidence 
that their reversible airways disease was under control. If it 
was not possible to reduce the dose of oral steroid over 
3 weeks the patient was withdrawn from the study. All data 
involving the exacerbation, its severity, type of action 
taken, days absent from work and the PEF during the 
exacerbation were recorded on a specifically designed 
module in the case record form. 
SAFETY 
Blood samples for routine haematology, biochemistry, 
markers of bone turnover and serum cortisol levels, and 
urine for routine urinanalysis were taken (between 0800 and 
1000 h) from fasting patients at the pre-study visit, at the 
end of treatment (irrespective of when this occurred) and at 
the follow-up visit if haematological and biochemical values 
were abnormal at the end of treatment. Blood samples were 
also taken for markers of bone turn-over (calcium, collagen 
and osteocalcin) and serum cortisol every 4 weeks during 
the treatment period. Adverse events, including acute 
exacerbations, were recorded daily in the diary card by 
each patient and at every clinic visit on the case record form 
by the investigator. 
STATISTICAL ANALYSIS 
The sample size calculation required 189 patients in each 
treatment group, based on a 90% power to detect a 
difference equal or greater than 15 1 min-’ in PEF. The 
trial analysis was conducted on an intent-to-treat basis and 
included all patients randomized to treatment. All analyses 
were two-sided at the 5% significance level and no 
adjustments were made for multiple testing. Variables on 
an interval or ratio scale were analysed using analysis of 
covariance with the baseline measurement as the covariate. 
Variables, where appropriate, were log-transformed to 
satisfy distributional assumptions for parametric tests and 
for variables on the ordinal scale the absolute change from 
baseline was analysed using the Wilcoxon rank sum test. 
All data were analysed using SPSSWIN software (SPSS 
Inc., Chicago, IL, U.S.A.), version 6.1.2, and for data not 
subject to statistical analysis, e.g. markers of bone turn- 
over, only descriptive analyses were conducted. Adverse 
events were coded by body system in accordance with 
WHO criteria. 
Mean morning and evening PEF, daytime and night-time 
symptom scores and percentage symptom-free days and 
nights were computed overall and for weeks 14, 5-8, 9-16 
and 17-24. Treatment effect on PEF was calculated as the 
mean difference between treatments adjusted for the 
differences in baseline PEF and the 95% confidence limits. 
The treatment effect was tested for significance by ANOVA 
with the mean run-in PEF as covariate and included 
countries as factors in the model. The effect of treatments 
on daytime and night-time symptom score were analysed 
using the Wilcoxon rank-sum test for the median symptom 
scores, the change in median symptom scores from baseline 
and the percentage symptom-free day and nights. The 
difference in the need for rescue medication was analysed 
by comparing the percentage rescue-free nights and days 
using ANOVA with baseline measurements as covariate. 
The significance of the effect of treatment on FEVi, FVC 
and PEF at each visit was analysed using ANOVA models 
with the end of run-in values as covariate and country as 
factor. 
The incidence of exacerbations was obtained from four 
sources; the acute exacerbation module in the case record 
form, the response to a ‘yes/no’ question at each clinic visit, 
the diary card and the adverse event section in the case 
record form. All sections were subjected to thorough cross- 
checking. The definition of asthma exacerbation when 
completing the exacerbation module was at the discretion 
of the investigator. The definition of asthma exacerbation 
from the adverse events section of the case record form was 
taken as anything referring to asthma. This resulted in some 
discrepancy between the two sections that could not be 
completely reconciled retrospectively. In view of the lack of 
experience with the exacerbation module, not all the 
statistical analyses performed had been pre-defined in the 
protocol, but they were undertaken to further explore this 
important component .of asthma control. The statistical 
analysis was as follows: Fisher’s exact test to compare the 
number of patients who had more than one exacerbation; 
actuarial survival analysis techniques to determine time to 
first exacerbation and exacerbation-free time; Wilcoxon 
statistics to compare disease-free distributions and ANO- 
VA to compare the mean lowest PEF during exacerbation 
using mean daily-run-in PEF as covariate and country as 
factor. Serial serum cortisol levels were compared using 
ANOVA with country as factor and baseline cortisol 
measurements as covariate, and the incidence of adverse 
events was compared using Fisher’s exact test. 
Results 
A total of 548 patients entered the run-in period, of which 
395 were randomized to treatment with either FP or BUD. 
The majority of patients who withdrew during the run-in 
period did so because they did not fulfil the run-in criteria 
(67%). Other reasons (patients could withdraw for more 
than one reason) were lack of efficacy (lo/u), adverse events 
(9%) failure to return (9%) and other (17%). The two 
treatment groups were well matched for all aspects of 
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TABLE 1. Baseline patient demography and clinical characteristics 
Treatment group 
Characteristic Fluticasone propionate Budesonide 
Patients (n) 
Age (years), mean (range) 
Sex 
Males 
Females 
Race 
Caucasian 
Other 
History of atopy 
Smoker 
Current 
Ex-smoker 
Mean change (%) in FEVi in 
response to inhaled salbutamol 
400 Pg 
800 piit 
Pre-treatment 
FEVi (1) mean (SD) 
FVC (l), mean, (SD) 
PEF (1 mini), mean, (SD) 
Concurrent medication, n (%) 
Oral steroids for exacerbations, n (%) 
198 197 
49 (19-76) 47 (18-75) 
100 99 
98 98 
193 189 
5 8 
117 118 
24 35 
81 71 
12.8 12.9 
22.3 22.8 
2.1 (0.8) 2.2 (0.9) 
3.2 (1.1) 3.3 (1.1) 
364 (111) 370 (110) 
77 (39%) 64 (34%) 
42 (21%) 40 (20%) 
FEVi, forced expiratory volume in 1 set; FVC, forced vital capacity; PEF, peak 
expiratory flow rate. 
demography, clinical history, pre-treatment lung function 
and response to challenge with inhaled salbutamol (Table 1). 
The adjusted mean differences between the two treat- 
ments with respect to FEVi, FVC and PEF measured at 
each visit were in favour of FP throughout the treatment 
period and the difference reached statistical significance for 
FEVi at weeks 5-8 (0.09 1; P = 0.04), 9-16 (0.10 1; 
P = 0.03) and 17-24 (0.12 1; P = 0.02). Although there 
was no significant difference between the two treatments on 
morning and evening PEF, the adjusted mean PEF was 
consistently higher both overall and for each treatment 
period for patients treated with FP (Fig. 1). In addition, the 
upper 95% confidence limits indicated that the FP-BUD 
difference in PEF exceeded 15 1 min- ’ both overall and for 
each time segment following 4 weeks treatment for morning 
PEF, and for weeks 9-16 and 17-24 for evening PEF 
(Table 2). 
The difference in mean morning PEF on the last 7 days 
of treatment relative to the last 7 days of the run-in 
expressed as % predicted PEF was classified according to 
those patients with clinically relevant changes. An impor- 
tant increase in PEF was classified as an increase of more 
than lo%, a mild increase as a less than 10% increase, a 
mild decrease as between 0 and 10% and an important 
decrease in PEF as a decrease of 10% or more. When 
looking at the response to treatment in this way, there was a 
5-8 9-16 17-24 
Treatment period (weeks) 
FIG. 1. Difference in adjusted mean peak expiratory flow 
rates for different time periods of patients receiving either 
fluticasone propionate (FP; 2000 pg daily) or budesonide 
(BUD; 2000 pg daily) over a 24-week period. Results are 
expressed as FP -BUD. 
significant difference (P = 0.04) between FP and BUD 
with respect to the distribution of response between the 
four categories (Wilcoxon rank-sum test). Patients treated 
with FP were more likely to experience an important 
increase in PEF than those treated with BUD, whereas 
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TABLE 2. Effect of treatment with fluticasone propionate 
(FP; 2000 pg daily) or budesonide (BUD; 2000 1.18 daily) on 
peak expiratory flow (PEF) in asthma patients 
Mean FP-BUD 95 % confidence 
PEF* (1 min-‘) limits (1 min- ‘) 
_. 
Morning PEF i 
Weeks l-4 
Weeks 5-8 
Weeks 9-16 
Weeks 17-24 
Weeks l-24 
Evening PEF 
Weeks l-4 
Weeks 5-8 
Weeks 9-16 
Weeks 17-24 
Weeks l-24 
4.6 -2.0 11.2 
7.6 -1.2 16.3 
7.8 -2.1 17.6 
5.4 -5.3 16.1 
6.9 - 1.4 15.2 
2.7 -3.8 9.2 
3.7 -4.7 12.2 
5.5 -4.1 15.0 
4.7 -6.1 15.4 
4.7 -3.5 12.8 
* Data were adjusted for baseline PEF. 
patients treated with BUD were more likely to experience 
an important decrease in PEF than those treated with FP 
(Table 3). 
These preferential effects in favour of FP were confirmed 
by statistically significant changes in other clinical para- 
meters. There was a statistically significant treatment effect 
in favour of FP on the median daytime symptom scores for 
weeks 5-8 (P = 0.05) and 9-16 (P = 0.01). The adjusted 
mean percentage symptom-free days (31.5% on FP and 
22.8% on BUD) also reached statistical significance overall 
(P = 0.02) and during weeks 17-24 (P = 0.02). During 
each treatment period the difference in percentage rescue- 
free days (42.7% FP vs. 33.7% BUD) reached statistical 
significance overall (P = O-02) and during weeks 17-24 
(P = 0.02). 
There was no significant difference between the two 
treatments with respect to the number of patients with one 
TABLE 3. Classification of the difference between end-of- 
study and pre-treatment mean peak expiratory flow (PEF), 
expressed as percentage of the predicted PEF, and the 
distribution asthma patients (number and percentage) 
receiving either fluticasone propionate (FP; 2000 pg daily) 
or budesonide (BUD; 2000 pg daily) in these categories 
FP BUD 
Change* (n> (%I (a> (%I 
Decrease of > 10% 5 (3-O)% 14 (8.5)% 
Decrease between 0 and 10% 34 (20.6)% 36 (21.8)% 
Increase between 0 and 10% 62 (37.6)% 67 (40.6)% 
Increase > 10% 64 (38.8)% 48 (29.1)% 
*Change in mean morning PEF of the last 7 days of the 
run-in and the last 7 days of the scheduled treatment 
periods expressed as % predicted PEF. Overall statistically 
significant difference in favour of FP in change in % 
predicted PEF between FP- and BUD-treated groups 
(P = 0.04). 
or more exacerbations (Table 4). The number of exacerba- 
tions recorded in the exacerbation-specific module in the 
case record form was 203, 113 (33.8% of patients) in the FP 
group and 90 (28.4% of patients) in the BUD group, there 
being no significant difference between the two treatments. 
The majority of exacerbations (85% in the FP group and 
83% in the BUD group) required only one of the actions 
described in Table 5. The percentages of patients treated 
with FP and BUD who remained exacerbation-free after 
180 days were 60 and 68%, respectively, and there was no 
statistical difference in this distribution. The mean time to 
resolution of an exacerbation was, however, less in the FP 
compared with the BUD group (11.0 vs. 14.7 days; 
P = 0*035), and the mean duration of all exacerbations 
(for an individual patient) was shorter (18.5 vs. 23.6 days; 
P = 0.12). In addition, the number of days absent from 
TABLE 4. Patients experiencing one or more exacerbations during 24-week treatment with 
either fluticasone propionate (FP; 2000 pg daily) or budesonide (BUD; 2000 pg daily) 
(n ::98) 
BUD Fisher’s exact test 
(n = 197) (8 
Patients with 21 exacerbation (n) 
Definition of exacerbation 
67 56 
Any event containing ‘asthma’ or a 
reference to exacerbation e.g. 
bronchitis, pneumonia 
Only events containing the word 
‘asthma’ 
Data from exacerbation module in 
case report form 
69 (34.8%) 58 (29.4%) 0.28 
53 (26.8%) 46 (23.4%) 0.49 
67 (33.8%) 56 (28.4%) 0.28 
618 J. H. HEINIG ETAL. 
TABLE 5. Summary of the incidence, duration, severity and management of exacer- 
bations recorded in the exacerbation module 
FP (2000 pg daily) BUD (2000 pug daily) 
I2 (%I ?l ’ (%I 
Patients with 21 exacerbation (n) 
Exacerbations (n) 
Actions required* 
One 
Two 
Three 
Type of action 
Home management 
GP to patient’s home 
Patient to GP surgery 
Hospital out-patient visit 
Admitted to hospital 
Maximal exacerbation severity 
Mild (none of below) 
Moderate (oral steroids) 
Severe (in patient or accident 
and emergency) 
61 (34.0) 56 (28.0) 
113 (56.0) 90 (44.0) 
96 (85.0) 75 (83.3) 
15 (13.3) 13 (14.4) 
2 (1.8) 2 (2.2) 
48 (31.2) 31 (25.4) 
13 (8.4) 11 (9.0) 
31 (20.1) 30 (24.6) 
52 (33.8) 43 (35.2) 
10 (6.5) 7 (5.7) 
24 (35.8) 16 (28.6) 
32 (47.8) 30 (53.6) 
11 (16.4) 10 (17.9) 
“Denotes any combination of management at home, visit to GP surgery, hospital 
outpatient or hospital inpatient. 
work was lower in FP-treated patients (P = 0.012) 
compared with those receiving BUD (Fig. 2), and the 
lowest PEF recorded during an exacerbation was higher in 
the FP group compared with the BUD group (301.7 and 
263.7 1 min-‘, respectively; P = 0.07). 
At these microgram equivalent doses of FP and BUD no 
difference in the systemic corticosteroid effect was ob- 
served. The pre-treatment serum cortisol levels for FP and 
BUD were 356.7 (SD 192.3) and 380.5 (SD 231.7) nmol 1-I 
respectively, and these decreased over the treatment period 
by 16.7% for patients receiving FP and by 13.9% for those 
receiving BUD (P = 0.43). After 24 weeks of treatment the 
mean cortisol levels were 285.5 (SD 189.4) and 315.0 (SD 
184.3) mmol 1-l with FP and BUD, respectively. 
In addition, there was no significant effect of either 
corticosteroid on any of the markers of bone turn-over 
during the treatment period. Calcium levels were stable 
during FP and BUD treatment, remaining close to the pre- 
treatment values of 41.54 and 41.32 ng ml-‘, respectively. 
Collagen levels increased slowly but consistently over the 
24-week treatment period from 91.91 to 107.05 pg 1-l in 
the FP-treated group, and from 98.01 to 113.74 pg 1-l in 
the BUD-treated group. Osteocalcin levels decreased slowly 
but consistently from 4.90 to 4.19 ng ml-’ in patients 
receiving FP and from 5.17 to 4.27 ng ml-’ in those 
receiving BUD. 
The number of adverse events reported, the number of 
patients with one or more events (78% for FP and 77% for 
BUD) and the most frequently occurring events (Table 6) 
were equally distributed between the two treatment groups. 
P=O.12 
P=O.O35 
Time to resolution 
P= 0.012 
Duration Days of work 
Exacerbation characteristic 
FIG. 2. The mean time to resolution (days), mean duration 
of all exacerbations experienced by one patient (days) and 
mean number of days absent from work of patients 
receiving either fluticasone propionate (FP; 2000 pg daily, 
0) or budesonide (BUD; 2000 pg daily, q ) over a 24-week 
period. 
Discussion 
The results of this study indicate that FP, at a dose of 
2000 ,ug daily, produced preferential changes in lung 
function and decreased the severity of exacerbations 
compared with BUD at the same dosage. This was achieved 
without producing any greater systemic adverse effect than 
BUD. Neither drug had an effect on markers of bone turn- 
over or clinically relevant effects on serum cortisol levels. 
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TABLE 6. Summary of most frequently reported adverse 
events (>2% in either treatment group) during treatment 
with either fluticasone propionate (FP; 2000 pg daily) or 
budesonide (BUD; 2000 pg daily) over a 24-week period 
Body system FP BUD 
Patients with an adverse event (n) 155 152 
Respiratory system (%) 35.0 36.3 
Body-as-a-whole/general (%) 22.7 22.0 
Central and peripheral nervous system (%) 10.4 11.5 
Immunological system (%) 12.0 8.0 
Gastrointestinal system (%) 9.0 6.8 
Musculoskeletal (%) 1.6 2.7 
Skin and appendages (%) 1.2 2.7 
The inclusion and exclusion criteria to the study 
probably resulted in the exclusion of the patients who 
would have benefited most from the treatments in this 
study. Even though the study only recruited patients who, 
in the opinion of the investigator, were appropriate for 
treatment with these doses of inhaled corticosteroid, the 
exclusion criteria meant that those patients who experi- 
enced frequent exacerbations were excluded. This resulted 
in patients with more moderate asthma being treated in the 
study and this is reflected in the baseline lung function 
scores. Consequently, it is likely that the patients had not 
required such high doses of corticosteroid and both 
treatments could be considered to be on or near the plateau 
of the patient’s corticosteroid dose-response curve for PEF 
(27). It is possible, however, that the corticosteroid dose- 
response curve is different for each individual characteristic 
of asthma control (28) and this is why treatment with the 
more potent corticosteroid, FP, resulted in significantly 
better improvements in some aspects of asthma control 
relative to BUD. 
corticosteroid. This is relevant because it has been shown 
that the systemic absorption of FP from the lungs is greater 
in healthy volunteers than in patients with asthma (29). The 
reason for this is because a greater proportion of the inhaled 
dose reaches the site of absorption (the alveoli) rather than 
the site of action (the bronchioles). Similarly, for a given 
dose of FP greater systemic absorption would be expected in 
patients with moderate asthma relative to patients with 
severe asthma. In addition to drug deposition in the lungs 
being affected by the severity of asthma, there are consider- 
able differences in drug delivery to the lungs between 
inhalation devices (30), and the dependence of these devices 
on inhalation flow rates (31). It is therefore not advised to 
extrapolate the results of lung deposition studies to other 
drugs in either the same device or different devices (32). 
Overall, therefore, at equal doses FP is more effective 
than BUD at producing clinically relevant improvements in 
lung function and in reducing the daytime asthma symptom 
score in patients with severe asthma. There was no overall 
difference in the number of exacerbations between the two 
treatment groups, but patients treated with FP experienced 
less severe asthma exacerbations (seen as time to resolution 
of an exacerbation and time absent from work) than those 
receiving BUD. This may have important pharmaco- 
economic benefits for FP and warrants further investiga- 
tion. Both treatments were well tolerated. In retrospect, the 
patients recruited into this study probably had no need for 
such high doses of inhaled corticosteroid but, irrespective of 
this, FP at microgram equivalent doses showed evidence of 
superior efficacy to BUD with respect to lung function and 
severity of asthma exacerbations without producing any 
greater adverse systemic effect. 
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asthma exacerbation are needed. 
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